Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision updated to v3.5.4, indicating a new version of the study record history. This update does not change the underlying study data or trial details.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s displayed revision/version number updates from **v3.5.2** to **v3.5.3**, indicating a site release without changing the trial record text.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded Revision: v3.5.2. Removed Revision: v3.5.0.SummaryDifference0.1%

- Check49 days agoChange DetectedAdded a new Study Status section to the version history to reflect the trial's current status across revisions. An entry from 2026-03-12 was removed.SummaryDifference0.3%

- Check71 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3 from the history.SummaryDifference0.1%

- Check78 days agoChange DetectedA new site revision 3.4.3 adds Oversight and Study Status entries, replacing the previous revision 3.4.2.SummaryDifference0.5%

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.